Silence Therapeutics Management
Management criteria checks 2/4
Silence Therapeutics' CEO is Craig Tooman, appointed in Feb 2022, has a tenure of 3.08 years. total yearly compensation is $9.30M, comprised of 6.5% salary and 93.5% bonuses, including company stock and options. directly owns 0.024% of the company’s shares, worth $39.73K. The average tenure of the management team and the board of directors is 2.4 years and 5.1 years respectively.
Key information
Craig Tooman
Chief executive officer
US$9.3m
Total compensation
| CEO salary percentage | 6.5% |
| CEO tenure | 3.1yrs |
| CEO ownership | 0.02% |
| Management average tenure | 2.4yrs |
| Board average tenure | 5.1yrs |
Recent management updates
Recent updates
Silence Therapeutics plc (NASDAQ:SLN) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough
Mar 22
These Analysts Think Silence Therapeutics plc's (NASDAQ:SLN) Sales Are Under Threat
Mar 06We're Keeping An Eye On Silence Therapeutics' (NASDAQ:SLN) Cash Burn Rate
Mar 04Risks Still Elevated At These Prices As Silence Therapeutics plc (NASDAQ:SLN) Shares Dive 26%
Jan 28Silence Therapeutics plc (NASDAQ:SLN) May Have Run Too Fast Too Soon With Recent 54% Price Plummet
Dec 10Some Shareholders Feeling Restless Over Silence Therapeutics plc's (NASDAQ:SLN) P/S Ratio
Oct 04Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 18Silence Therapeutics plc's (NASDAQ:SLN) Shareholders Might Be Looking For Exit
Jun 17Here's Why We're Not Too Worried About Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation
May 21Need To Know: Analysts Are Much More Bullish On Silence Therapeutics plc (NASDAQ:SLN) Revenues
Feb 07Subdued Growth No Barrier To Silence Therapeutics plc (NASDAQ:SLN) With Shares Advancing 65%
Nov 27Silence Therapeutics wins FDA’s fast track status for blood cancer therapy
Sep 08Silence Therapeutics prices 5.95M ADSs at $9.50/share
Aug 12New finance chief for Silence Therapeutics
Jan 06CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | n/a | n/a | -US$45m |
| Sep 30 2024 | n/a | n/a | -US$79m |
| Jun 30 2024 | n/a | n/a | -US$51m |
| Mar 31 2024 | n/a | n/a | -US$44m |
| Dec 31 2023 | US$9m | US$603k | -US$54m |
| Sep 30 2023 | n/a | n/a | -US$52m |
| Jun 30 2023 | n/a | n/a | -US$53m |
| Mar 31 2023 | n/a | n/a | -US$53m |
| Dec 31 2022 | US$7m | US$557k | -US$50m |
| Sep 30 2022 | n/a | n/a | -US$40m |
| Jun 30 2022 | n/a | n/a | -US$47m |
| Mar 31 2022 | n/a | n/a | -US$51m |
| Dec 31 2021 | US$3m | US$452k | -US$53m |
Compensation vs Market: Craig's total compensation ($USD9.30M) is above average for companies of similar size in the US market ($USD1.45M).
Compensation vs Earnings: Craig's compensation has increased whilst the company is unprofitable.
CEO
Craig Tooman (59 yo)
3.1yrs
Tenure
US$9,303,571
Compensation
Mr. Craig A. Tooman, MBA, serves as President, Chief Executive Officer and Executive Director of Silence Therapeutics plc since February 21, 2022. He has been a Supervisory Director of Curevac N. V. since...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.1yrs | US$9.30m | 0.024% $ 39.7k | |
| Executive VP | 3.1yrs | US$3.18m | 0.0011% $ 1.8k | |
| Executive VP and Chief Research & Development Officer | 1.9yrs | US$2.32m | 0.0092% $ 15.4k | |
| Chief Scientific Officer | 1.3yrs | no data | no data | |
| Head of IR & Corporate Communications | no data | no data | no data | |
| Chief Human Resources Officer | less than a year | no data | no data | |
| Senior VP and Chief Intellectual Property & Innovation Officer | 2.5yrs | no data | no data | |
| Senior Vice President of Regulatory Affairs & Quality Assurance | 4.7yrs | no data | no data | |
| Chief Technical Operations Officer | 2.3yrs | no data | no data | |
| Chief Medical Officer | no data | no data | no data |
2.4yrs
Average Tenure
60yo
Average Age
Experienced Management: SLN's management team is considered experienced (2.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.1yrs | US$9.30m | 0.024% $ 39.7k | |
| Independent Non-Executive Director | 6.8yrs | US$234.57k | 0.0053% $ 8.9k | |
| Chairman of Scientific Advisory Board | 5.1yrs | no data | no data | |
| Independent Non-Executive Director | 4.2yrs | US$226.92k | 0.0092% $ 15.4k | |
| Independent Chairman of the Board | 5.9yrs | US$512.47k | 0.078% $ 130.4k | |
| Member of Scientific Advisory Board | 5.1yrs | no data | no data | |
| Independent Non-Executive Director | 5.9yrs | US$232.02k | 0.011% $ 17.8k | |
| Member of Scientific Advisory Board | 5.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.2yrs | no data | no data |
5.1yrs
Average Tenure
62yo
Average Age
Experienced Board: SLN's board of directors are considered experienced (5.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/23 00:16 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Silence Therapeutics plc is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | BMO Capital Markets Equity Research |
| Konstantinos Biliouris | BMO Capital Markets Equity Research |
| Thomas Shrader | BTIG |